CD274 and cancer: There was nonsignificant association between PD-L1 and recurrence-free survival (RFS) (HR = 1.43, 95% CI = 0.89-2.29, <i>p</i> = 0.134), cancer-specific survival (CSS) (HR = 1.51, 95% CI = 0.80-2.87, <i>p</i> = 0.203), or disease-free survival (DFS) (HR = 1.53, 95% CI = 0.88-2.65, <i>p</i> = 0.13).